Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be announcing earnings results tomorrow before market hours. Here’s what to expect. ANI Pharmaceuticals beat analysts’ revenue expectations by 8.5% last quarter, reporting revenues of $190.6 million, up 44.8% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and full-year revenue guidance exceeding analysts’ expectations. Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free. This quarter, analysts are expecting ANI Pharmaceuticals’s revenue to grow 30.7% year on year to $179.6 million, improving from the 28.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.38 per share.ANI Pharmaceuticals Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 5.7% on average. Looking at ANI Pharmaceuticals’s peers in the generic pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 5.5%, missing analysts’ expectations by 3.4%, and Amphastar Pharmaceuticals reported flat revenue, falling short of estimates by 2%. Amneal traded down 2.4% following the results. Read our full analysis of Amneal’s results here and Amphastar Pharmaceuticals’s results here. Investors in the generic pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. ANI Pharmaceuticals is up 8.8% during the same time and is heading into earnings with an average analyst price target of $81.88 (compared to the current share price of $71.82). Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. View Comments
Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...